{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:30:27Z","timestamp":1791174627218,"version":"4.1.0"},"reference-count":27,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2012,8,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> Children's Oncology Group study AALL00P2 was designed to assess the feasibility and safety of adding nelarabine to a BFM 86\u2013based chemotherapy regimen in children with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL). <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> In stage one of the study, eight patients with a slow early response (SER) by prednisone poor response (PPR; \u2265 1,000 peripheral blood blasts on day 8 of prednisone prephase) received chemotherapy plus six courses of nelarabine 400 mg\/m<jats:sup>2<\/jats:sup> once per day; four patients with SER by high minimal residual disease (MRD; \u2265 1% at day 36 of induction) received chemotherapy plus five courses of nelarabine; 16 patients with a rapid early response (RER) received chemotherapy without nelarabine. In stage two, all patients received six 5-day courses of nelarabine at 650 mg\/m<jats:sup>2<\/jats:sup> once per day (10 SER patients [one by MRD, nine by PPR]) or 400 mg\/m<jats:sup>2<\/jats:sup> once per day (38 RER patients; 12 SER patients [three by MRD, nine by PPR]). <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> The only significant difference in toxicities was decreased neutropenic infections in patients treated with nelarabine (42% with v 81% without nelarabine). Five-year event-free survival (EFS) rates were 73% for 11 stage one SER patients and 67% for 22 stage two SER patients treated with nelarabine versus 69% for 16 stage one RER patients treated without nelarabine and 74% for 38 stage two RER patients treated with nelarabine. Five-year EFS for all patients receiving nelarabine (n = 70) was 73% versus 69% for those treated without nelarabine (n = 16). <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Addition of nelarabine to a BFM 86\u2013based chemotherapy regimen was well tolerated and produced encouraging results in pediatric patients with T-ALL, particularly those with a SER, who have historically fared poorly. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2011.40.8724","type":"journal-article","created":{"date-parts":[[2012,6,27]],"date-time":"2012-06-27T07:48:02Z","timestamp":1340783282000},"page":"2753-2759","source":"Crossref","is-referenced-by-count":81,"title":["Pilot Study of Nelarabine in Combination With Intensive Chemotherapy in High-Risk T-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group"],"prefix":"10.1200","volume":"30","author":[{"given":"Kimberly P.","family":"Dunsmore","sequence":"first","affiliation":[{"name":"Kimberly Dunsmore, Children's Oncology Group (COG) and University of Virginia Health Sciences Center, Charlottesville, VA; Meenakshi Devidas and Stephen Linda, COG and University of Florida, Gainesville, FL; Michael J. Borowitz, Johns Hopkins Medical Institutions, Baltimore, MD; Naomi Winick, University of Texas Southwestern Medical Center, Dallas, TX; Stephen P. Hunger, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO; William L. Carroll, New York University (NYU)..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi","family":"Devidas","sequence":"additional","affiliation":[{"name":"Kimberly Dunsmore, Children's Oncology Group (COG) and University of Virginia Health Sciences Center, Charlottesville, VA; Meenakshi Devidas and Stephen Linda, COG and University of Florida, Gainesville, FL; Michael J. Borowitz, Johns Hopkins Medical Institutions, Baltimore, MD; Naomi Winick, University of Texas Southwestern Medical Center, Dallas, TX; Stephen P. Hunger, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO; William L. Carroll, New York University (NYU)..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"Linda","sequence":"additional","affiliation":[{"name":"Kimberly Dunsmore, Children's Oncology Group (COG) and University of Virginia Health Sciences Center, Charlottesville, VA; Meenakshi Devidas and Stephen Linda, COG and University of Florida, Gainesville, FL; Michael J. Borowitz, Johns Hopkins Medical Institutions, Baltimore, MD; Naomi Winick, University of Texas Southwestern Medical Center, Dallas, TX; Stephen P. Hunger, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO; William L. Carroll, New York University (NYU)..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Borowitz","sequence":"additional","affiliation":[{"name":"Kimberly Dunsmore, Children's Oncology Group (COG) and University of Virginia Health Sciences Center, Charlottesville, VA; Meenakshi Devidas and Stephen Linda, COG and University of Florida, Gainesville, FL; Michael J. Borowitz, Johns Hopkins Medical Institutions, Baltimore, MD; Naomi Winick, University of Texas Southwestern Medical Center, Dallas, TX; Stephen P. Hunger, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO; William L. Carroll, New York University (NYU)..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Winick","sequence":"additional","affiliation":[{"name":"Kimberly Dunsmore, Children's Oncology Group (COG) and University of Virginia Health Sciences Center, Charlottesville, VA; Meenakshi Devidas and Stephen Linda, COG and University of Florida, Gainesville, FL; Michael J. Borowitz, Johns Hopkins Medical Institutions, Baltimore, MD; Naomi Winick, University of Texas Southwestern Medical Center, Dallas, TX; Stephen P. Hunger, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO; William L. Carroll, New York University (NYU)..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Hunger","sequence":"additional","affiliation":[{"name":"Kimberly Dunsmore, Children's Oncology Group (COG) and University of Virginia Health Sciences Center, Charlottesville, VA; Meenakshi Devidas and Stephen Linda, COG and University of Florida, Gainesville, FL; Michael J. Borowitz, Johns Hopkins Medical Institutions, Baltimore, MD; Naomi Winick, University of Texas Southwestern Medical Center, Dallas, TX; Stephen P. Hunger, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO; William L. Carroll, New York University (NYU)..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L.","family":"Carroll","sequence":"additional","affiliation":[{"name":"Kimberly Dunsmore, Children's Oncology Group (COG) and University of Virginia Health Sciences Center, Charlottesville, VA; Meenakshi Devidas and Stephen Linda, COG and University of Florida, Gainesville, FL; Michael J. Borowitz, Johns Hopkins Medical Institutions, Baltimore, MD; Naomi Winick, University of Texas Southwestern Medical Center, Dallas, TX; Stephen P. Hunger, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO; William L. Carroll, New York University (NYU)..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce M.","family":"Camitta","sequence":"additional","affiliation":[{"name":"Kimberly Dunsmore, Children's Oncology Group (COG) and University of Virginia Health Sciences Center, Charlottesville, VA; Meenakshi Devidas and Stephen Linda, COG and University of Florida, Gainesville, FL; Michael J. Borowitz, Johns Hopkins Medical Institutions, Baltimore, MD; Naomi Winick, University of Texas Southwestern Medical Center, Dallas, TX; Stephen P. Hunger, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO; William L. Carroll, New York University (NYU)..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.9.3122.3122"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609045714"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<600::AID-CNCR24>3.0.CO;2-4"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.522"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401310"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401938"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401973"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.116"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20429"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1616"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-070342"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.2679"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-338707"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.12.4386"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808273390904"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.8.2691"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.3.1226"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0317"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.15.12.1601"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06527.x"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.199"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.426"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401741"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1977.1"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20743"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.1031"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2011.40.8724","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T22:25:58Z","timestamp":1653517558000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2011.40.8724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,1]]},"references-count":27,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2012,8,1]]}},"alternative-id":["10.1200\/JCO.2011.40.8724"],"URL":"https:\/\/doi.org\/10.1200\/jco.2011.40.8724","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,1]]}}}